Expression of matrix metalloproteinases, their inhibitors, and lysyl oxidase in myocardial samples from dogs with end-stage systemic and cardiac diseases

American Journal of Veterinary Research

Volumn 74, Issue 2, 2013, Pages 216-223

  Fonfara, Sonja ^a,b   Hetzel, Udo ^a,c   Tew, Simon R ^a   Cripps, Peter ^a   Dukes McEwan, Joanna ^a   Clegg, Peter D ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMIODARONE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; MATRIX METALLOPROTEINASE; MESSENGER RNA; MEXILETINE; PIMOBENDAN; PROTEIN LYSINE 6 OXIDASE; SPIRONOLACTONE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANIMAL TISSUE; AORTA STENOSIS; ARTICLE; CELL INFILTRATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DOG; DYSPLASIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HISTOLOGY; LIPOMATOSIS; LYMPHOCYTIC INFILTRATION; MALE; MYOCARDIAL DISEASE; NONHUMAN; PATHOLOGY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR CELL; VALVULAR HEART DISEASE;

ANIMALS; CARDIOMYOPATHY, DILATED; CLUSTER ANALYSIS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION; GENETIC MARKERS; HEART DISEASES; MALE; MATRIX METALLOPROTEINASES; MYOCARDIUM; ORGAN SPECIFICITY; PROTEIN-LYSINE 6-OXIDASE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84873333066     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.2.216     Document Type: Article

References (59)

1. Spinale FG, Coker ML, Heung LJ, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000;102:1944-1949.
2. Spinale FG. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002;90:520-530.
3. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
4. Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol 2004;43:68-76.
5. Zile MR, Desantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011;4:246-256.
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
7. Sivakumar P, Gupta S, Sarkar S, et al. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 2008;307:159-167.
8. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
9. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010;48:445-453.
10. Koskivirta I, Kassiri Z, Rahkonen O, et al. Mice with tissue inhibitor of metalloproteinases 4 (Timp4) deletion succumb to induced myocardial infarction but not to cardiac pressure overload. J Biol Chem 2010;285:24487-24493.
11. Bradham WS, Moe G, Wendt KA, et al. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol 2002;282:H1288-H1295.
12. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004;9:53-61.
13. Nelson LO, Thompson PA. Cardiovascular dysfunction in dogs associated with critical illnesses. J Am Anim Hosp Assoc 2006;42:344-349.
14. Picard F, Brehm M, Fassbach M, et al. Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients. Clin Res Cardiol 2006;95:261-269.
15. Batlle M, Perez-Villa F, Garcia-Pras E, et al. Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients. Transplant Proc 2007;39:2344-2346.
16. Gilbert SJ, Wotton PR, Tarlton JF, et al. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res 1997;34:377-383.
17. Oyama MA, Chittur S. Genomic expression patterns of cardiac tissues from dogs with dilated cardiomyopathy. Am J Vet Res 2005;66:1140-1155.
18. Ljungvall I, Rajamaki MM, Crosara S, et al. Evaluation of plasma activity of matrix metalloproteinase-2 and -9 in dogs with myxomatous mitral valve disease. Am J Vet Res 2011;72:1022-1028.
19. Aupperle H, Thielebein J, Kiefer B, et al. An immunohistochemical study of the role of matrix metalloproteinases and their tissue inhibitors in chronic mitral valvular disease (valvular endocardiosis) in dogs. Vet J 2009;180:88-94.
20. Oyama MA, Chittur SV. Genomic expression patterns of mitral valve tissues from dogs with degenerative mitral valve disease. Am J Vet Res 2006;67:1307-1318.
21. Obayashi K, Miyagawa-Tomita S, Matsumoto H, et al. Effects of transforming growth factor-beta3 and matrix metalloproteinase-3 on the pathogenesis of chronic mitral valvular disease in dogs. Am J Vet Res 2011;72:194-202.
22. Smith-Mungo LI, Kagan HM. Lysyl oxidase: properties, regulation and multiple functions in biology. Matrix Biol 1998;16:387-398.
23. Lopez B, Gonzalez A, Hermida N, et al. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am J Physiol Heart Circ Physiol 2010;299:H1-H9.
24. Adam O, Theobald K, Lavall D, et al. Increased lysyl oxidase expression and collagen cross-linking during atrial fibrillation. J Mol Cell Cardiol 2011;50:678-685.
25. Villari B, Campbell SE, Schneider J, et al. Sex-dependent differences in left ventricular function and structure in chronic pressure overload. Eur Heart J 1995;16:1410-1419.
26. Arshad A, Moss AJ, Foster E, et al. Cardiac resynchronization therapy is more effective in women than in men: the MADITCRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol 2011;57:813-820.
27. Fonfara S, Hetzel U, Tew SR, et al. Leptin expression in dogs with cardiac disease and congestive heart failure. J Vet Intern Med 2011;25:1017-1024.
28. Fonfara S, Tew SR, Cripps P, et al. Increased blood mRNA expression of inflammatory and anti-fibrotic markers in dogs with congestive heart failure. Res Vet Sci 2012;93:879-885.
29. Garvican ER, Vaughan-Thomas A, Redmond C, et al. Chondrocytes harvested from osteochondritis dissecans cartilage are able to undergo limited in vitro chondrogenesis despite having perturbations of cell phenotype in vivo. J Orthop Res 2008;26:1133-1140.
30. Clements DN, Carter SD, Innes JF, et al. Analysis of normal and osteoarthritic canine cartilage mRNA expression by quantitative polymerase chain reaction. Arthritis Res Ther 2006;8:R158.
31. Clements DN, Fitzpatrick N, Carter SD, et al. Cartilage gene expression correlates with radiographic severity of canine elbow osteoarthritis. Vet J 2009;179:211-218.
32. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25:402-408.
33. Tidholm A, Jonsson L. Histologic characterization of canine dilated cardiomyopathy. Vet Pathol 2005;42:1-8.
34. Aupperle H, Thielebein J, Kiefer B, et al. Expression of genes encoding matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in normal and diseased canine mitral valves. J Comp Pathol 2009;140:271-277.
35. Aupperle H, Disatian S. Pathology, protein expression and signaling in myxomatous mitral valve degeneration: comparison of dogs and humans. J Vet Cardiol 2012;14:59-71.
36. Fox PR. Pathology of myxomatous mitral valve disease in the dog. J Vet Cardiol 2012;14:103-126.
37. Gilliver SC, Ruckshanthi JP, Atkinson SJ, et al. Androgens influence expression of matrix proteins and proteolytic factors during cutaneous wound healing. Lab Invest 2007;87:871-881.
38. Liao X, Thrasher JB, Pelling J, et al. Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology 2003;144:1656-1663.
39. Mahmoodzadeh S, Dworatzek E, Fritschka S, et al. 17β-estradiol inhibits matrix metalloproteinase-2 transcription via MAP kinase in fibroblasts. Cardiovasc Res 2010;85:719-728.
40. Schulz R. Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 2007;47:211-242.
41. Fonfara S, Hetzel U, Tew S, et al. Increased myocardial cytokine expression in dogs with systemic and naturally occurring cardiac diseases. Am J Vet Res 2012;73:241-248.
42. Horn MA, Graham HK, Richards MA, et al. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J Mol Cell Cardiol 2012;53:82-90.
43. Nelson OL, Thompson PA. Cardiovascular dysfunction in dogs associated with critical illnesses. J Am Anim Hosp Assoc 2006;42:344-349.
44. Serra M, Papakonstantinou S, Adamcova M, et al. Veterinary and toxicological applications for the detection of cardiac injury using cardiac troponin. Vet J 2010;185:50-57.
45. Flynn A, Chokkalingam Mani B, Mather PJ. Sepsis-induced cardiomyopathy: a review of pathophysiologic mechanisms. Heart Fail Rev 2010;15:605-611.
46. Sciarretta S, Paneni F, Palano F, et al. Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clin Sci (Lond) 2009;116:467-477.
47. Brundel BJ, Melnyk P, Rivard L, et al. The pathology of atrial fibrillation in dogs. J Vet Cardiol 2005;7:121-129.
48. Anne W, Willems R, Roskams T, et al. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial fibrillation. Cardiovasc Res 2005;67:655-666.
49. Zhong JQ, Zhang W, Li Y, et al. Changes in metalloproteinase and tissue inhibitor of metalloproteinase during tachycardiainduced cardiomyopathy by rapid atrial pacing in dogs. Cardiology 2006;106:22-28.
50. Creemers EE, Davis JN, Parkhurst AM, et al. Deficiency of TIMP-1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003;284:H364-H371.
51. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006;113:2089-2096.
52. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-1715.
53. Polyakova V, Miyagawa S, Szalay Z, et al. Atrial extracellular matrix remodelling in patients with atrial fibrillation. J Cell Mol Med 2008;12:189-208.
54. Lopez B, Querejeta R, Gonzalez A, et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53:236-242.
55. Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006;97:532-537.
56. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol 2010;48:461-467.
57. Reinhardt D, Sigusch HH, Hensse J, et al. Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP. Heart 2002;88:525-530.
58. Peterson JT, Li H, Dillon L, et al. Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 2000;46:307-315.
59. Wess G, Schulze A, Butz V, et al. Prevalence of dilated cardiomyopathy in Doberman Pinschers in various age groups. J Vet Intern Med 2010;24:533-538.